Home » Takeda’s Zika Vaccine Candidate Fast-Tracked by FDA
Takeda’s Zika Vaccine Candidate Fast-Tracked by FDA
Japanese drugmaker Takeda received a fast-track designation from the FDA for its Zika virus vaccine candidate, TAK-426.
The fast-track designation was given to expedite the development and review process, as there are currently no medicines or vaccines for the virus.
The candidate is currently in a Phase 1 trial under an investigational new drug application. If the results of the trial are supportive, Takeda plans to move into Phase 2 development as soon as possible.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May